METHODS FOR TREATMENT OF METASTATIC CANCER TYPES, USING AXL TRAP RECEPTORS Russian patent published in 2022 - IPC A61K31/337 A61K38/45 A61P35/00 A61P35/04 

FIELD: medicine.

SUBSTANCE: invention relates to medicine and concerns a method for the treatment of human platinum-resistant metastatic ovarian cancer. The method includes administration to a patient of a therapeutically effective dose of a soluble variant of AXL polypeptide, where the soluble variant of AXL polypeptide does not have a transmembrane AXL domain; does not have a fibronectin (FN) domain; has one Ig1 domain and one Ig2 domain; and has a number of amino acid modifications of AXL sequence of a wild type (SEQ ID NO: 1), consisting of: Gly32Ser, Ala72Val, Asp87Gly, Val92Ala, and Gly127Arg; where the specified number of amino acid modifications increases affinity of binding of AXL polypeptide with growth arrest specific protein 6 (GAS6), and where the soluble variant of AXL polypeptide is fused with Fc region with a peptide linker. At the same time, the administration scheme includes 15 mg/kg of the soluble variant of polypeptide AXL, administered every two weeks, and 80 mg/m² of paclitaxel administered once a week.

EFFECT: method provides for effective and safe treatment of platinum-resistant ovarian cancer.

4 cl, 9 dwg, 3 tbl, 8 ex